FilingIndex
8-KThe WireRoutine

Reg FD Disclosure

Filed Dec 15, 2021 · 4y ago · Accession 0001193125-21-357356

Plain English

Material event — a significant development the company must disclose promptly.

Read the source below for the full document.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2021     THERMO FISHER SCIENTIFIC INC. (Exact name of Registrant as specified in its Charter)       Delaware   1-8002   04-2209186 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.) 168 Third Avenue Waltham , Massachusetts 02451 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (781) 622-1000     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $1.00 par value   TMO   New York Stock Exchange 0.750% Notes due 2024   TMO 24A   New York Stock Exchange 0.125% Notes due 2025   TMO 25B   New York Stock Exchange 2.000% Notes due 2025   TMO 25   New York Stock Exchange 1.400% Notes due 2026   TMO 26A   New York Stock Exchange 1.450% Notes due 2027   TMO 27   New York Stock Exchange 1.750% Notes due 2027   TMO 27B   New York Stock Exchange 0.500% Notes due 2028   TMO 28A   New York Stock Exchange 1.375% Notes due 2028   TMO 28   New York Stock Exchange 1.950% Notes due 2029   TMO 29   New York Stock Exchange 0.875% Notes due 2031   TMO 31   New York Stock Exchange 2.375% Notes due 2032   TMO 32   New York Stock Exchange 2.875% Notes due 2037   TMO 37   New York Stock Exchange 1.500% Notes due 2039   TMO 39   New York Stock Exchange 1.875% Notes due 2049   TMO 49   New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).              ☐ Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 7.01 Regulation FD Disclosure. On December 15, 2021, Thermo Fisher Scientific Inc. (the “Company”) notified the holders of its (i) $1,200,000,000 aggregate principal amount of 2.950% Senior Notes due 2026 (the “2026 Notes”) and (ii) $750,000,000 aggregate principal amount of 3.200% Senior Notes due 2027 (the “2027 Notes” and, together with the 2026 Notes, the “Notes”) that it will redeem all of the Notes on December 30, 2021 (the “Redemption Date”). The 2026 Notes will be redeemed at a redemption price equal to the greater of (i) 100% of the principal amount of the 2026 Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of the 2026 Notes to be redeemed discounted to the Redemption Date on a semi-annual basis at a comparable treasury rate plus 25 basis points, plus accrued and unpaid interest on the 2026 Notes to be redeemed, if any, to, but excluding, the Redemption Date. The 2027 Notes will be redeemed at a redemption price equal to the greater of (i) 100% of the principal amount of the 2027 Notes to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of the 2027 Notes to be redeemed discounted to the Redemption Date on a semi-annual basis at a comparable treasury rate plus 20 basis points, plus accrued and unpaid interest on the 2027 Notes to be redeemed, if any, to, but excluding, the Redemption Date. The Company intends to fund the aggregate redemption price of approximately $1.95 billion using cash on hand. Cautionary Statement Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the Company’s statements about its intended source of funds for the redemption. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to general economic conditions and related uncertainties. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the Company’s most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, which are on file with the SEC and available in the “Investors” section of the Company’s website under the heading “SEC Filings,” and other documents the Company files with the SEC. While the Company may elect to update forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing the Company’s views as of any date subsequent to the date of this Current Report on Form 8-K. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.       THERMO FISHER SCIENTIFIC INC. Date: December 15, 2021     By:   /s/ Michael A. Boxer       Michael A. Boxer       Senior Vice President, General Counsel and Secretary
Filing details
Ticker
TMO
CIK
97745
Form type
8-K
Filing date
Dec 15, 2021
Report date
Dec 15, 2021
Document
d229743d8k.htm
Size
272 KB